Evidence map›Paper›PMID 30045773›Full record

ReviewMolecular cancer2018

Critical role of FOXO3a in carcinogenesis.

Ying Liu, Xiang Ao, Wei Ding, Murugavel Ponnusamy, Wei Wu, Xiaodan Hao, Wanpeng Yu, Yifei Wang, Peifeng Li, Jianxun Wang

Open access · goldAbstract readReview
In one paragraph

Review in Molecular cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 277 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
277citing papers in PubMed, 2 pooled it
17.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

277 citing papers in PubMed, 2 syntheses or guidelines pooled it, 537 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Longevity-associatedTranslational lung cancer research · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Research progress on the mechanism of FOXO protein in sepsis.Apoptosis : an international journal on programmed cell death · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Review

217 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ying LiuInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Xiang AoInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Wei DingDepartment of comprehensive internal medicine, Affiliated Hospital, Qingdao University, Qingdao, 266003, China.
Murugavel PonnusamyInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Wei WuInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Xiaodan HaoInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Wanpeng YuInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Yifei WangInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China.
Peifeng LiInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China. peifli@qdu.edu.cn.
Jianxun WangInstitute for Translational Medicine, College of Medicine, Qingdao University, Qingdao, 266021, China. jianxunwang16@163.com.
Qingdao University · CNAffiliated Hospital of Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FOXO3a is a member of the FOXO subfamily of forkhead transcription factors that mediate a variety of cellular processes including apoptosis, proliferation, cell cycle progression, DNA damage and tumorigenesis. It also responds to several cellular stresses such as UV irradiation and oxidative stress. The function of FOXO3a is regulated by a complex network of processes, including post-transcriptional suppression by microRNAs (miRNAs), post-translational modifications (PTMs) and protein-protein interactions. FOXO3a is widely implicated in a variety of diseases, particularly in malignancy of breast, liver, colon, prostate, bladder, and nasopharyngeal cancers. Emerging evidences indicate that FOXO3a acts as a tumor suppressor in cancer. FOXO3a is frequently inactivated in cancer cell lines by mutation of the FOXO3a gene or cytoplasmic sequestration of FOXO3a protein. And its inactivation is associated with the initiation and progression of cancer. In experimental studies, overexpression of FOXO3a inhibits the proliferation, tumorigenic potential, and invasiveness of cancer cells, while silencing of FOXO3a results in marked attenuation in protection against tumorigenesis. The role of FOXO3a in both normal physiology as well as in cancer development have presented a great challenge to formulating an effective therapeutic strategy for cancer. In this review, we summarize the recent findings and overview of the current understanding of the influence of FOXO3a in cancer development and progression.

Indexed as

Disease ProgressionFemaleForkhead Box Protein O3Gene Expression Regulation, NeoplasticHumansMaleMicroRNAsMutationNeoplasmsProtein Processing, Post-TranslationalForkhead Box Protein O3FOXO3 protein, humanMicroRNAsCancerFOXO3aInactivationPost-translational modificationsTumor suppressor

Identifiers

PMID30045773
PMCPMC6060507
OpenAlexW2884819597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.